Vnitr Lek 2005, 51(6):644-646

Hrozba světové pandemie obezity - editorial

J. Rybka
Diabetologické centrum IK IPVZ a WHO-CC, vedoucí prof. MUDr. Jaroslav Rybka, DrSc., Interní klinika IPVZ Ba»ovy krajské nemocnice, Zlín, přednosta prim. MUDr. Ivo Oral, CSc.

Received: April 5, 2005; Published: June 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rybka J. Hrozba světové pandemie obezity - editorial. Vnitr Lek. 2005;51(6):644-646.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bray GA. Drug treatment of overweight. In: Bray GA (ed). Contemporary diagnosis and management of obesity. 2. ed. Newton: Handbooks in Healthcare 2003: 263-300.
    2. Eckel RH. Obesity: a disease or a physiologic adaptation for survival? In: Eckel RH (ed). Obesity mechanisms and clinical management. Philadelphia: Lippincott Williams & Wilkins 2003: 3-30.
    3. Gray GB. Obesity is a chronic, relapsing neurochemical disease. International Journal of Obesity 2004; 28: 34-38. Go to original source... Go to PubMed...
    4. Guven A, Koksal A, Cetinkaya A et al. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004; 6: 50-55. Go to original source... Go to PubMed...
    5. Hainer V. Obezita dosahuje rozměrů celosvětové epidemie. 13. Evropský kongres, Praha - květen 2004. Lékařské listy 2004; 22: 10.
    6. Hainer V. Obezita. Praha: Triton 2003.
    7. Hardie GD. 13. Evropský kongres, Praha květen 2004. In: Kopecký J Energetický stav buněk je klíč. Lékařské listy 2004; 22: 13.
    8. Hazenberg BP. Randomised double-blind, a placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-158 Go to original source... Go to PubMed...
    9. James WPT, Astrup A, Finer A et al for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised of sibutramine trial. Lancet 2000; 356: 2119-2125. Go to original source... Go to PubMed...
    10. Kuneąová M. Obezita - etiopatogeneze, diagnostika a léčba. Interní medicína pro praxi 2004; 6: 435-440.
    11. Peter WF, Scott MG. The Metabolic Syndrom. Practical Guide to Originis and Treatment. Part I. Circulation 2003; 108: 1422-1425. Go to original source... Go to PubMed...
    12. Ryan DH, Bray GA. Pharmacological Treatment of Obesity. In: Lebovitz HE (ed). Therapy for Diabetes Mellitus and Related Disorders. Alexandria (Virginia). ADA 2004; 17: 136-148.
    13. Sramek JJ, Leibowitz MT, Weinstein SP et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled b-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002; 16: 13-19. Go to original source... Go to PubMed...
    14. Sucharda P. Sibutramin v léčbě obezity. Medicína po promoci 2004; 5: 65-69.
    15. Svačina ©. Obezita, diabetes, ateroskleróza. Kardiofórum 2004; 2: 11-13.
    16. Vozár J, Wasczuk P, Záhoráková A et al. Sibutramin v liečbe obezity u diabetikov 2. typu. Diabetes a obezita 2001; 2: 44-51.
    17. Wyatt HL, Hill JO. Jakou roli mají hrát antiobezitika? Medicína po promoci 2004; 2: 6-13.
    18. ©mahelová A. Výsledky multicentrického sledování léčby sibutraminem u obézních diabetiků v České republice. Vnitř Lék 2005; 51(6): 676-679.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.